303 related articles for article (PubMed ID: 32551985)
1. Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes.
Peiró ÓM; Cediel G; Bonet G; Rojas S; Quintern V; Carrasquer A; González-Del-Hoyo M; Sanz E; Bardají A
Biomarkers; 2020 Jul; 25(5):402-409. PubMed ID: 32551985
[No Abstract] [Full Text] [Related]
2. Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
Nikorowitsch J; Borchardt T; Appelbaum S; Ojeda F; Lackner KJ; Schnabel RB; Blankenberg S; Zeller T; Karakas M
J Am Heart Assoc; 2020 Apr; 9(8):e015452. PubMed ID: 32299288
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction.
Sörensen NA; Nikorowitsch J; Neumann JT; Rübsamen N; Goßling A; Hartikainen TS; Blankenberg S; Westermann D; Zeller T; Karakas M
Clin Res Cardiol; 2019 Dec; 108(12):1386-1393. PubMed ID: 30989318
[TBL] [Abstract][Full Text] [Related]
4. Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease.
Al-Badri A; Tahhan AS; Sabbak N; Alkhoder A; Liu C; Ko YA; Vaccarino V; Martini A; Sidoti A; Goodwin C; Ghazzal B; Beshiri A; Murtagh G; Mehta PK; Quyyumi AA
J Am Heart Assoc; 2020 Apr; 9(8):e015515. PubMed ID: 32301366
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome.
Chenevier-Gobeaux C; Lemarechal H; Doumenc B; Peschanski N; Claessens YE; Borderie D; Ray P
Clin Biochem; 2021 Jun; 92():19-24. PubMed ID: 33662350
[TBL] [Abstract][Full Text] [Related]
6. Long-term prognostic value of growth differentiation factor-15 in acute coronary syndromes.
Peiró ÓM; García-Osuna Á; Ordóñez-Llanos J; Cediel G; Bonet G; Rojas S; Quintern V; Bardají A
Clin Biochem; 2019 Nov; 73():62-69. PubMed ID: 31369736
[TBL] [Abstract][Full Text] [Related]
7. SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease.
Hodges G; Lyngbæk S; Selmer C; Ahlehoff O; Theilade S; Sehestedt TB; Abildgaard U; Eugen-Olsen J; Galløe AM; Hansen PR; Jeppesen JL; Bang CN
Scand Cardiovasc J; 2020 Dec; 54(6):339-345. PubMed ID: 32400206
[TBL] [Abstract][Full Text] [Related]
8. Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.
Koller L; Stojkovic S; Richter B; Sulzgruber P; Potolidis C; Liebhart F; Mörtl D; Berger R; Goliasch G; Wojta J; Hülsmann M; Niessner A
JACC Heart Fail; 2017 Apr; 5(4):268-277. PubMed ID: 28359415
[TBL] [Abstract][Full Text] [Related]
9. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
[TBL] [Abstract][Full Text] [Related]
10. Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death.
Ghasemzedah N; Hayek SS; Ko YA; Eapen DJ; Patel RS; Manocha P; Al Kassem H; Khayata M; Veledar E; Kremastinos D; Thorball CW; Pielak T; Sikora S; Zafari AM; Lerakis S; Sperling L; Vaccarino V; Epstein SE; Quyyumi AA
Circ Cardiovasc Qual Outcomes; 2017 Mar; 10(3):. PubMed ID: 28280039
[TBL] [Abstract][Full Text] [Related]
11. Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
Ishikawa H; Izumiya Y; Shibata A; Ichikawa Y; Yamaguchi T; Yamaguchi Y; Kitada R; Iwata S; Ehara S; Tomita S; Hanatani A; Yoshiyama M
Heart Vessels; 2020 May; 35(5):681-688. PubMed ID: 31741050
[TBL] [Abstract][Full Text] [Related]
12. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
[TBL] [Abstract][Full Text] [Related]
13. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
14. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.
Eapen DJ; Manocha P; Ghasemzadeh N; Patel RS; Al Kassem H; Hammadah M; Veledar E; Le NA; Pielak T; Thorball CW; Velegraki A; Kremastinos DT; Lerakis S; Sperling L; Quyyumi AA
J Am Heart Assoc; 2014 Oct; 3(5):e001118. PubMed ID: 25341887
[TBL] [Abstract][Full Text] [Related]
15. Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain.
Lyngbæk S; Andersson C; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen P; Eugen-Olsen J; Hansen PR; Jeppesen JL
Clin Chem; 2013 Nov; 59(11):1621-9. PubMed ID: 23842203
[TBL] [Abstract][Full Text] [Related]
16. Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study.
Walter JE; Amrein MLF; Schäfer I; Zimmermann T; Lopez-Ayala P; Boeddinghaus J; Twerenbold R; Puelacher C; Nestelberger T; Wussler D; Honegger U; Badertscher P; Eugen-Olsen J; Koechlin L; Fahrni G; Jeger R; Kaiser C; Zellweger M; Mueller C
Biomarkers; 2022 May; 27(3):278-285. PubMed ID: 35112976
[TBL] [Abstract][Full Text] [Related]
17. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
Lyngbæk S; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen PM; Eugen-Olsen J; Jeppesen JL; Hansen PR
Am J Cardiol; 2012 Dec; 110(12):1756-63. PubMed ID: 22981263
[TBL] [Abstract][Full Text] [Related]
20. Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography.
Sommerer C; Zeier M; Morath C; Reiser J; Scharnagl H; Stojakovic T; Delgado GE; März W; Kleber ME
Sci Rep; 2019 Jan; 9(1):475. PubMed ID: 30679668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
